Head-to-head · WeighScore
NextMeds vs Somira Health
The verdict
NextMeds takes it — 66.3/100 to 62.5/100.
NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NextMeds | Somira Health |
|---|---|---|
| WeighScore | 66.3/100 | 62.5/100 |
| Grade | C | C |
| Scorecard rank | #191 | #269 |
| Semaglutide | $129/mo (plus a separate fee, compounded) | $190/mo (compounded) |
| Tirzepatide | $179/mo (plus a separate fee, compounded) | $285/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #191 · C
Strengths
- Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
- Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
- Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
- Free, no-obligation online assessment before you pay anything
Where it loses points
- Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
- Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
- A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #269 · C
Strengths
- Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
- Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
- Free overnight shipping, with syringes and alcohol wipes included in every order
- Simple, fast online intake reviewed by a licensed provider; no insurance required
- Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide
Where it loses points
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- The compounding pharmacy partner is not named
- State-availability list is not published
- No LegitScript certification displayed
- New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.